Ph.D., Co-Founder and Chief Executive Officer, Astrocyte Pharmaceuticals Inc.
Dr. Korinek is Astrocyte Pharmaceuticals’ CEO and Co-Founded the company in 2014. Previously, he was at Pfizer for almost 10 years in a number of strategic and operational R&D positions, most recently serving as the Vice President of Worldwide R&D Business Operations. Dr. Korinek and his organization managed the Worldwide R&D annual operating plan process, including coordination of annual investment business plans from all of Pfizer’s Research Units and functional Partner Lines and the setting of annual investment and budget targets. He has broad experience from early discovery through full development, small and large therapeutic modalities, and many disease areas. At Pfizer, he championed and secured $24M in capital for a long term Project and Resource Planning productivity program that was successfully implemented over 2011-2014. Dr. Korinek also managed Pfizer’s R&D Program Management Office (PMO) for the Pfizer-Wyeth integration, and the PMO for Pfizer WRD’s 2011 “Engine for Sustainable Innovation” strategic restructuring involving the reduction of Pfizer’s overall R&D 2012 spend from $8.0-8.5B to $6.5-7.0B.
Dr. Korinek previously worked as an Engagement Manager at the strategy consulting firm L.E.K. Consulting, where he worked with ~40 life sciences companies ranging from biotech startups to large pharmaceutical companies on issues such as strategic planning, portfolio prioritization, and M&A due diligence. He earned his Ph.D. from Harvard University’s Molecular and Cellular Biology Department, where he researched the molecular linkages of cell polarity signals to the cytoskeleton and published in leading journals including Science.
Concussions, stroke and other traumatic brain injuries (TBI) can lead to permanent brain damage. Our entrepreneurial researchers explore new treatments and therapeutics to treat and prevent damage from TBI. Hear from our panel of experts in neuroscience and sports medicine as they share their latest innovations and treatments. UT Health San Antonio panel includes: Jim […]